Miraculins Releases CEO Letter to Shareholders
WINNIPEG, MANITOBA--(Marketwired - Jan 20, 2014) - Miraculins
Inc. (TSX-VENTURE:MOM), ("Miraculins" or the "Company") a medical
diagnostic company focused on acquiring, developing and
commercializing diagnostic and risk assessment technologies for
unmet clinical needs, today issues the following letter to
shareholders from Company President & CEO Christopher
Moreau:
Dear Fellow Shareholders:
As Miraculins' President and CEO, and as a shareholder myself, I
want to take this opportunity to thank you for your decision to
become an investor and for your ongoing support as we continue to
progressively build our company.
I also want to take a moment to provide you with some additional
information regarding the recent announcement to consolidate
Miraculins shares, along with some further perspective on the
company, its strengths, and our long-term goals and objectives.
Miraculins Stock
Consolidation
From time to time, companies listed on the TSX Venture exchange
will announce a consolidation of their share structure when the
company is planning to change direction, change its name, or to
start fresh as part of a major corporate reorganization. This is
not the case with the proposed Miraculins stock consolidation. I
want all shareholders to clearly understand that Miraculins remains
committed to achieving the goal of building a world-class medical
device company by bringing our innovative technologies to those in
need around the world, and generating the financial rewards that
can result for our shareholders. The consolidation is subject to
the approval of the TSX Venture Exchange.
The Board of Director's decision to consolidate our stock
following the approval of a special resolution at Miraculins' 2013
AGM, was primarily based on the objective of achieving a more
rational share price that better reflects the company's technology
value and its future commercial promise. The proposed consolidation
is also anticipated to enable the company to be more attractive to
the widest range of potential investors.
Miraculins
Team
Because Miraculins is a public company, with investors around
the globe, it is impossible for me to meet or speak with each one
of you personally. If I could, I would tell you in the strongest
words possible that in addition to the ground-breaking Scout DS®,
PreVu®, and Preeclampsia technologies being steadily advanced, one
of Miraculins greatest assets is the dedicated team of management
and staff I have the privilege of leading.
Behind the scenes, working with enthusiasm and perseverance, are
specialists in multiple key areas including quality assurance,
regulatory, research and development, engineering, manufacturing,
sales and marketing, communications, intellectual property, as well
as logistics and business development. Working alongside of them
are highly-skilled experts providing important legal, accounting
and corporate finance guidance. I am proud to be the President and
CEO of a company with team members whose individual and collective
tenacity and desire to see Miraculins succeed is exceptional.
Staying the
Course
There is no question that our path is a challenging one, and
that the commercial introduction of new medical technologies
carries with it significant obstacles along the way. Difficult
capital markets can make it hard to access much needed capital
investment on a timely basis for operations and growth.
Additionally, long buying cycles can delay product launches and
initiatives, and the highly regulated industry we work in can also
add significant costs to the bottom line.
Having said this, the commensurate rewards and upside can be
significant for shareholders as well, as we continue to work
towards realizing our business objectives and goals. While we are
still in the early stages of introducing these new technologies to
the market, we remain committed to our present path of innovative,
stage-based commercialization and growth.
We believe strongly in our technologies, in their capacity to
impact patients in need worldwide, and we believe in the
corresponding potential of our company to build and achieve
significant value for shareholders along the way.
Thank you again for your ongoing support.
Christopher J. Moreau, President and CEO & Shareholder,
Miraculins Inc.
About Miraculins Inc.
Miraculins is a medical diagnostic company focused on acquiring,
developing and commercializing non-invasive technologies for unmet
clinical needs. A significant number of promising diagnostic
opportunities remain un-commercialized because of the sizable gap
between the discovery stage, when research institutions are
typically involved, and the commercialization stage, when the
larger commercial enterprises become interested. Miraculins has
direct experience in bridging this gap. The Company's PreVu® POC
Test is a revolutionary new coronary artery disease risk assessment
technology that measures cholesterol levels in a patient's skin
non-invasively, painlessly and without the need for fasting. The
Company's Scout DS® system is the first non-invasive diabetes
testing system designed to provide a highly sensitive and
convenient method for measuring diabetes related biomarkers in the
skin, the accumulation of which are accelerated by abnormal blood
sugar levels and oxidative stress. Unlike current testing methods,
a Scout DS® test requires no blood draw, no fasting, and no waiting
for a lab result. The product has been used and validated in
thousands of patients around the world. The Company's preeclampsia
program is partnered with Alere Inc., one of the world's largest
diagnostic companies. For more information visit
www.miraculins.com
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Caution Regarding Forward-Looking Information
"Certain statements contained in this press release
constitute forward-looking information within the meaning of
applicable Canadian provincial securities legislation
(collectively, "forward-looking statements"). These forward-looking
statements include statements regarding the receipt of TSX Venture
Exchange approval for the proposed share consolidation, the
anticipated effects of the consolidation, the rewards and upside
for shareholders, the realization of the company's business
objectives and goals and the potential of the company to build and
achieve significant value for shareholders. These forward-looking
statements relate to, among other things, our objectives, goals,
targets, strategies, intentions, plans, beliefs, estimates and
outlook, including, without limitation, our anticipated future
operating results, and can, in some cases, be identified by the use
of words such as "believe," "anticipate," "expect," "intend,"
"plan," "will," "may" and other similar expressions. In addition,
any statements that refer to expectations, projections or other
characterizations of future events or circumstances are
forward-looking statements.
These statements reflect management's current beliefs and
are based on information currently available to management. Certain
material factors or assumptions are applied in making
forward-looking statements, and actual results may differ
materially from those expressed or implied in such statements.
Important factors that could cause actual results to differ
materially from these expectations include, among other things:
Miraculins' early stage of development, lack of product revenues
and history of operating losses, uncertainties related to clinical
trials and product development, rapid technological change,
uncertainties related to forecasts, competition, potential product
liability, additional financing requirements and access to capital,
unproven markets, supply of raw materials, income tax matters,
management of growth, partnerships for development and
commercialization of technology, effects of insurers' willingness
to pay for products, system failures, dependence on key personnel,
foreign currency risk, risks related to regulatory matters and
risks related to intellectual property and other risks detailed
from time to time in Miraculins' filings with Canadian securities
regulatory authorities, as well as Miraculins' ability to
anticipate and manage the risks associated with the foregoing.
Additional information about these factors and about the material
factors or assumptions underlying such forward-looking statements
may be found in the body of this news release. Miraculins cautions
that the foregoing list of important factors that may affect future
results is not exhaustive. When relying on Miraculins'
forward-looking statements to make decisions with respect to
Miraculins investors and others should carefully consider the
foregoing factors and other uncertainties and potential
events.
These risks and uncertainties should be considered carefully
and prospective investors should not place undue reliance on the
forward-looking statements. Although the forward-looking statements
contained in this press release are based upon what management
believes to be reasonable assumptions, Miraculins cannot provide
assurance that actual results will be consistent with these
forward-looking statements. Miraculins undertakes no obligation to
update or revise any forward-looking statements."
PreVu® and Scout DS® are
registered trademarks of Miraculins Inc. All Rights Reserved.
2014.
Christopher J. MoreauPresident & CEOMiraculins
Inc.204-477-7599204-453-1546info@miraculins.comwww.miraculins.com
Miraculins Inc. (TSXV:MOM)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Miraculins Inc. (TSXV:MOM)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024